Myoclonus epilepsy with ragged-red fibers
Jun. 18, 2022
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Nusinersen is a splice-modulating antisense oligonucleotide indicated for the treatment of spinal muscular atrophy. Intrathecal nusinersen was approved by the U.S. Food and Drug Administration (FDA) in 2016. Another splice-modulating oligonucleotide, eteplirsen, was also approved earlier in 2016 for the treatment of Duchenne muscular dystrophy. The FDA granted fast track designation and priority review to the application for nusinersen. The drug also received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. Pharmacological data and results of clinical trials submitted for the approval of nusinersen can be viewed on the FDA website. Nusinersen was approved as a treatment for spinal muscular atrophy in the European Union in 2017.
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.